English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Aim : To pilot study the therapeutic effect of dexmedetomidine-induced sleep balance treatment (DISBT) on the chronic refractory primary insomnia patients. Methods : Forty-two patients with chronic refractory primary insomnia were randomly divided into two groups by random number table. Patients in DISBT group were given DISBT for 3 days, while patients in the control group were given conventional treatment for 3 day. Pittsburgh sleep quality index (PSQI), the hyperarousal scale (HAS), and Hamilton anxiety scale (HAMA) were evaluated and compared between the pre-treatment and post-1-week-treatment. Sleep architecture and electroencephalogram (EEG) spectrum were also recorded and compared pre-treatment and post-treatment. Results : The scores of PSQI and HAMA in both groups after treatment were lower than those before treatment ( P   0.05), the extreme score, introspectiveness score, react score of HAS in DISBT group after treatment were lower than those before treatment ( P  < 0.05). Conclusion : DISBT effectively reduced the insomnia patient cortex hyperarousal level, corrected disorder of sleep-awakening pathways and eased up insomnia symptom. It is an effective method for chronic refractory primary insomnia.

Effect of Dexmedetomidine-Induced Sleep Balance Treatment on the Chronic Refractory Primary Insomnia Patients